N/A N=142 Massive Iron Deposit Assessment
Iron Overload · Excessive Body Iron Burden
Primary: Hepatic Iron Content in the Liver Using Liver Biopsy — 19.8 mcg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=243 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
Phase 2 N=16 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only) — 7.8 10^9 Neutrophils per Liter
Phase 2 N=60 Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
Cardiac Iron Overload
Primary: Change in Cardiac Iron Content From Baseline to Month 12 — 1.09 ratio
Phase 2 N=203 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Sickle Cell Disease · Iron Overload · Hemolytic Anemia
Primary: The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment — 30; 17; 30; 8 participants
Phase 2 N=197 Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Transfusional Iron Overload · Transfusional Hemosiderosis
Primary: Core Study: Change From Baseline in Myocardial T2* (Magnetic Resonance T2-star (T2*) Technique for the Measurement of Tissue Iron) After 12 Months Treatment — 1.12; 1.07…
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Phase 2 N=9 Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Thalassemia Major With Severe Transfusional Iron Overload
Primary: Number of Participants With Improvement in Liver Iron Concentration — 3 Participants
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
Phase 2 N=173 Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Myelodysplastic Syndrome · Iron Overload
Primary: Number of Participants Reporting Adverse Events — 171 Participants
Phase 4 N=27 Post Hematopoietic Stem Cell Transplantation
Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths as a Measure of Safety and Tolerability — 25; 3; 0 Participants
Phase 3 N=70 Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study
Liver Iron Overload
Primary: The Relative Change From Baseline in Liver Iron Content (LIC) After Prolonged Use of Deferasirox — -21.9; -23.1 Percent change
Phase 2 N=51 Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
Transfusional Iron Overload · Beta-thalassemia
Primary: Change From Baseline in Liver Iron Concentration (LIC) at 96 Weeks — -1.75 mg/g — p=0.0765
N/A N=197 Iron Depletion and Replacement in Blood Donors
Anemia
Primary: Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation — 116; 17 Participants
Phase 2 N=49 Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
Iron Overload · Hereditary Hemochromatosis
Primary: Absolute Change of Serum Ferritin From Baseline to the End of Extension, by Dose Cohort (Extension Per-protocol Population) — -389.1; -610.5; -571.6 µg/L
Phase 2 N=102 Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Chronic Anemia · Transfusional Hemosiderosis
Primary: Absolute Change From Baseline in Liver Iron Concentration (LIC) to Year 1 — -10.9 mg Fe/g dw
Phase 3 N=100 Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
Iron Overload
Primary: Occurrence of Adverse Events — 212 Adverse Events
Phase 3 N=1,683 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Thalassemia · Sickle Cell Disease · Diamond Blackfan Anemia
Primary: Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events — 0; 0; 1; 4 Participants
Phase 2 N=30 Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Iron Overload Due to Repeated Red Blood Cell Transfusions
Primary: The Percentage of Patients in Each Treatment Group Who Experience Post-dose Increases in Liver Enzyme Levels That Are Considered a Safety Concern. — 0; 0; 0; 0…
Phase 2 N=22 Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
Thalassemia · Iron Overload
Primary: Efficacy of Combined Treatment With Deferasirox and Deferoxamine Over 12 Months — -6.2 mg/g
Phase 2 N=30 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Thalassemia Major
Primary: Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC) — -5.934 % change of hematocrit-adjusted volume
Phase 2 N=12 Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
Kidney Failure
Primary: Net Iron Delivery From SFP Via the Dialysate — 692 microgram
N/A N=60 Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Efficacy of 1020 mg of Ferumoxytol Over 15 Minutes. Hemoglobin Measurements Will Take Place at Four and Eight Week Visit. — 85; 58; 92; 86 percentage of participants
Phase 4 N=15 Iron Indices and Intravenous Ferumoxytol: Time to Steady State
Iron Deficiency Anemia
Primary: Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize — 2 weeks
Phase 2 N=185 Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).
Sickle Cell Disease
Primary: Number of Participants With Adverse Events After Start of ICL670 — 131; 49; 1; 2 participants
Phase 1 N=66 Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Impaired Renal Function
Primary: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 — 445892.7; 932688.3; 1531185.8; 1261081.6 ng*hr/ml
Phase 4 N=64 Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Beta Thalassemia Major Anemia · Iron Overload
Primary: The Percentage of Patients in Each Treatment Group Who Still Have a Serum Ferritin Level < 1000 Micrograms Per Liter (μg/L) at Month 12 — 21; 12 Participants — p=0.0446
N/A N=150 IV Iron for the Anemia of Traumatic Critical Illness
Trauma · ICU Anemia
Primary: RBC Transfusion — 47; 55 participants
N/A N=60 Duration of Red Blood Cell Storage Prior to Transfusion
Iron, Blood Level Abnormal
Primary: Non-transferrin-bound Iron Level (AUC) — 0.5588; 2.839; 3.684; 5.272 microMole*hr/L
Phase 4 N=17 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
Pediatric Congenital Heart Disease
Primary: Composite Image Quality Score Among 7 Anatomical Structures. — 3.9; 2.7 score on a scale